Respiratory dysfunction at 3 months after COVID-19 was related to the altered composition of gut microbiota, such as reduced Erysipelotrichaceae UCG-003 and increased Veillonella and Flavonifractor, which persistently elevated the plasma levels of gut barrier dysfunction marker lipopolysaccharide-binding protein (LBP) (Vestad et al., 2022). This evidence concerns the gene LBP and COVID-19.